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INTRODUCTION:
This research has the long-term goal of developing a test that will discriminate between prostate cancer (PrCA) and benign prostate disease. The PSA test is sensitive for prostate cancer but not specific -many elevated levels of PSA are associated with the diseases of chronic prostatitis (CP) or benign prostatic hyperplasia (BPH) [1] . If, after an elevated PSA test, our test could distinguish among these possibilities, we could better take advantage of the sensitivity of the PSA test, with the enhanced specificity resulting from our test. Among other benefits, this would be significant for reducing the need for prostate biopsies, with all its attendant costs and potential morbidities [2, 3, 4] . Our approach is to look for biomarkers present on circulating leukocytes that will distinguish among the three conditions. We hypothesize that it is likely such differences exist because of the very different natures of the inflammatory response in those conditions [5, 6] . The practical rationale for this approach is that circulating leukocytes are present in the easily accessible clinical specimen of blood, yet avoids the pitfalls of serum proteomics, in which highly abundant proteins make the identification of biomarkers extremely challenging [7] . More broadly, our proposed studies will add to our understanding of the complex relationship among inflammation, the immune system and the development of prostate cancer. This knowledge may aid in the earlier identification of cases destined to become clinically significant cancers, as opposed to those which may be present are not destined to achieve clinical significance [8] .
BODY: We hypothesize that benign and malignant prostatic disease will each produce proteomic changes in circulating leukocytes characteristic of their disease. By analyzing the proteomes of leukocytes, we are now able to discriminate between the two classes of disease non-invasively. To achieve these objectives, we utilized mass spectrometry to produce comprehensive proteomic profiles of peripheral leukocytes from individuals with elevated PSA, and correlated the results with those obtained by histologic examination of core-biopsy samples. Supporting data towards these goals are detailed below.
After completion of patient recruitment, we selected seven control samples and seven cancer samples of CD4+ T-lymphocytes that were judged to be "high-quality samples" based on purity assessed by FACS analysis, and in amount of cells ( Table 1 ). The two groups were matched in age, and PSA level. Proteins from the lymphocytes were digested with trypsin, and the resulting triptic peptides were purified using solid phase extraction columns.
The proteins were analyzed using a Thermo Scientific Orbitrap mass spectrometer. Each sample was analyzed twice, so the 14 samples produced 28 data sets. Proteins were identified using the MASCOT search engine (Matrix Science), and label free quantitation was performed using the peak ion intensities of the Progenesis software package (Nonlinear Dynamics). In total, we identified 1250 proteins, and obtained quantitative data for 922 of them. 385 proteins were identified as differentially expressed, with Anova p-values < 0.1.
As we've discussed in detail previously [9] , proteins can be differentially expressed, without being useful for class discrimination. We therefore selected a preliminary group of 65 proteins that appeared to discriminate between the two groups ( Table 2) . (We will refine the selection further using more sophisticated analytical approaches during our no-cost extension.)
Finally, we developed a simple signed-sum scoring metric, based on our previous efforts [9] . For each protein abundance measurement, a threshold value was determined, and a sample was given a positive score contribution if its level was above or below the threshold value. The total score from all 65 proteins are then computed for each sample, and plotted in figure 1. As can be seen, using this simple and preliminary approach, we can achieve reasonable separation between individuals with prostate cancer and benign prostate disease, even though each individual has an elevated PSA level. Two patients with pathology reports showing only enlargement or inflammation but no cancer had high scores. Because the samples were analyzed twice, there are four data points above the dashed line. Table 2 . The 65 proteins used to build preliminary discriminator.
We also explored the proteomic investigation of leukocytes from mice in order to compare lymphocytes from two strains of mice that are essentially genetically identical but differ markedly in their propensity to develop prostate tumors driven by a transgene. The isolation of lymphocytes from one or more groups of mice was based upon a protocol developed by the alliance for cellular signaling (AfCS -AfCS Procedure Protocol PP0000000100, Version 1, 02/19/02), with slight modification. Lymphocytes from mouse spleens were isolated using negative selection with the appropriate monoclonal antibodies coupled to magnetic microbeads. This strategy depletes non-lymphocytic cells from a mixed population of splenocytes. Anti-Mac-1/CD11b microbeads are included in the negative selection to improve the removal of myeloid cells. Lymphocye isolation was performed using an AutoMACS automatic magnetic bead cell sorter (Miltenyi Biotec). Results using tissue from 34 mice euthanized according to an IACUC-approved protocol are summarized in Table 3 . In some cases, cells from multiple mice were pooled (e.g. mice 12 -1 6) in order to isolate larger number of cells. We found results to be inconsistent, with variability in cell purity and viability. For these reasons, along with the fact that our primary goal is the analysis of human cells, work that was proceeding acceptably, and the short amount of time available, we chose to not pursue this work further.
BPH / CP PrCA
Signed Sum Score Table 3 . Summary of results of lymphocyte isolation from mice spleens.
KEY RESEARCH ACCOMPLISHMENTS:
• Have analyzed clinical sample proteomes from monocytes using shotgun mass spectrometry.
• Have demonstrated that the original hypothesis -that proteomic signatures of CD4+ lymphocytes has the potential to discriminate between prostate cancer and other prostate disease in the setting of elevated PSA levels.
REPORTABLE OUTCOMES:
1.) A manuscript detailing these results, which represent a significant step towards our long-range goal of developing a blood test that can discriminate between prostate cancer and benign prostatic disease is in preparation.
CONCLUSION:
We remain enthusiastic about the prospects for the development of a test utilizing molecular differences in circulating leukocytes for the identification of patients with prostate cancer. Such a test would be clinically useful for reducing the number of biopsies performed, considerably reducing health care-wide expenditures associated with this procedure. The proteins we have utilized in our preliminary discrimination signature can be validated with mass spectrometry and antibody-based methods, allowing for high confidence in the observed differences. If the differences prove to be robust, it will be appropriate to evaluate the observations in wider clinical populations, ideally such as the Prostate Cancer Clinical Trials Consortium (PCCTC). If one can increase the certainty that an elevated PSA is a result of prostate cancer, and not due to nonmalignant prostate disease, one could pursue evaluating lower PSA levels as indicators of cancer, to increase the sensitivity of the test. This of course is documented in the literature, but it is always concerns about the higher false positive rates that lower levels of PSA are not considered suitable for routine clinical use.
